Home Newsfeeds Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

byBenzinga Newsdesk

December 22, 2022

1 minute read

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

Analyst Ratings

Analyst Ratings for First Solar

By Benzinga Insights

March 23, 10:01 AM

First Solar (NASDAQ:FSLR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

FSLR

Sportsman’s Warehouse Likely To Report Lower Q4 Earnings – Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

By Lisa Levin

April 12, 7:34 AM

Sportsman's Warehouse Holdings, Inc. (NASDAQ: SPWH) is expected to report its fourth quarter and full-year 2022 financial results after the closing bell on April 12, 2023.

SPWH

Amazon’s Q2 Earnings Impress; Focus On AI And Margin Improvement Praised By Analysts

By Priya Nigam

August 4, 11:40 AM

Shares of Amazon.com, Inc. (NASDAQ: AMZN) climbed in early trading on Friday, after the company reported blowout profits for the second quarter.

AMZN

Trump Loyalist Pleads Guilty To Fraud, Furthering Legal Woes For Former President

By Shivdeep Dhaliwal

August 19, 12:19 AM

The former chief financial officer of the Trump Organization pleaded guilty to fraud on Thursday in the New York Supreme Court.

DWAC

Oppenheimer Downgrades Fate Therapeutics to Perform

Related Posts

Analyst Ratings for First Solar

Sportsman’s Warehouse Likely To Report Lower Q4 Earnings – Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

Amazon’s Q2 Earnings Impress; Focus On AI And Margin Improvement Praised By Analysts

Trump Loyalist Pleads Guilty To Fraud, Furthering Legal Woes For Former President